Publique en esta revista
Información de la revista
Vol. 7. Núm. E.
Stents recubiertos
Páginas 1E-7E (Julio 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 7. Núm. E.
Stents recubiertos
Páginas 1E-7E (Julio 2007)
Stents recubiertos
Acceso a texto completo
Situación actual de los stents liberadores de fármacos: nuevos desafíos y nuevas dudas. Introducción
Visitas
...
Juan Luis Delcán-Domíngueza,��
Autor para correspondencia
juanluisdelcan@yahoo.es

Correspondencia: Dr. J.L. Delcán-Domínguez. Unidad de Hemodinámica y Cardiología Intervencionista. Hospital de Madrid Montepríncipe. Avda. Montepríncipe, 25. 28660 Boadilla del Monte. Madrid. España.
, Santiago Jiménez-Valerob
a Servicio de Hemodinámica y Cardiología Intervencionista. Hospital de Madrid Montepríncipe. Madrid. España
b Sección de Hemodinámica y Cardiología Intervencionista. Servicio de Cardiología. Hospital Virgen de la Salud. Toledo. España
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Togni, F. Balmer, D. Pfiffner, W. Maier, A.M. Zeiher, B. Meier.
Working Group, Interventional Cardiology and Coronary Pathophysiology, European Society of Cardiology. Percutaneous coronary interventions in Europe 1992-2001.
Eur Heart J, 25 (2004), pp. 1208-1213
[2.]
A.R. Gruntzig, A. Senning, W.E. Siegenthaler.
Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.
N Engl J Med, 301 (1979), pp. 61-68
[3.]
D.L. Fischman, M.B. Leon, D.S. Baim, R.A. Schatz, M.P. Savage, I. Penn, et al.
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.
N Engl J Med, 331 (1994), pp. 496-501
[4.]
P.W. Serruys, P. De Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, et al.
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Stydy Group.
N Engl J Med, 331 (1994), pp. 489-495
[5.]
V. Rajagopal, S.G. Rockson.
Coronary restenosis: a review of mechanisms and management.
Am J Med, 115 (2003), pp. 547-553
[6.]
P.W. Serruys, B.H. Strauss, K.J. Beatt, M.E. Bertrand, J. Puel, A.F. Rickards.
Angiographic follow-up after placement of a self-expanding coronary-artery stent.
N Engl J Med, 324 (1991), pp. 13-17
[7.]
M.B. Leon, D.S. Baim, J.J. Popma, P.C. Gordon, D.E. Cutlip, K.K. Ho, et al.
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
N Engl J Med, 339 (1998), pp. 1665-1671
[8.]
C.R. Narins, E.J. Topol.
Reestenosis dentro de endoprótesis vasculares.
Tratado de cardiología intervencionista, 4.ª ed., pp. 469-488
[9.]
P.W. Serruys, A.T. Ong, L.A. Van Herwerden, J.E. Sousa, A. Jatene, J.J. Bonnier, et al.
Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial.
J Am Coll Cardiol, 46 (2005), pp. 575-581
[10.]
SoS Investigators.
Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial.
[11.]
M. Adamian, A. Colombo, C. Briguori, T. Nishida, F. Marsico, C. Di Mario, et al.
Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty.
J Am Coll Cardiol, 38 (2001), pp. 672-679
[12.]
M. Sabaté.
Estado actual de la braquiterapia intracoronaria.
Rev Esp Cardiol, 54 (2001), pp. 1197-1209
[13.]
R. Moreno.
Stents recubiertos y otros dispositivos antireestenosis.
Rev Esp Cardiol, 58 (2005), pp. 842-862
[14.]
M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, E. Ban Hayashi, M. Perin, RAVEL Study Group, et al.
Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions.
N Engl J Med, 346 (2002), pp. 1773-1780
[15.]
E. Grube, S. Silber, K.E. Hauptmann, R. Mueller, L. Buellesfeld, U. Gerckens, et al.
TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.
Circulation, 107 (2003), pp. 38-42
[16.]
A. Colombo, J. Drzewiecki, A. Banning, E. Grube, K. Hauptmann, S. Silber, TAXUS II Study Group, et al.
Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.
Circulation, 108 (2003), pp. 788-794
[17.]
E. Regar, P.W. Serruys.
El estudio RAVEL. Reestenosis del cero por ciento: ¡un sueño del cardiólogo hecho realidad!.
Rev Esp Cardiol, 55 (2002), pp. 459-462
[18.]
J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, SIRIUS Investigators, et al.
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
N Engl J Med, 349 (2003), pp. 1315-1323
[19.]
J. Schofer, M. Schluter, A.H. Gershlick, W. Wijns, E. García, E. Schampaert, et al.
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).
Lancet, 362 (2003), pp. 1093-1099
[20.]
E. Schampaert, E.A. Cohen, M. Schluter, F. Reeves, M. Traboulsi, L.M. Title, et al.
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
J Am Coll Cardiol, 43 (2004), pp. 1110-1115
[21.]
G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughnessy, J.T. Mann, TAXUS-IV Investigators, et al.
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
N Engl J Med, 350 (2004), pp. 221-231
[22.]
G.W. Stone, S.G. Ellis, L. Cannon, J.T. Mann, J.D. Greenberg, D. Spriggs, TAXUS V Investigators, et al.
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
JAMA, 294 (2005), pp. 1215-1223
[23.]
K.D. Dawkins, E. Grube, G. Guagliumi, A.P. Banning, K. Zmudka, A. Colombo, TAXUS VI Investigators.
Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial.
Circulation, 112 (2005), pp. 3306-3313
[24.]
P.A. Lemos, P.W. Serruys, R.T. Van Domburg, F. Saia, C.A. Arampatzis, A. Hoye, et al.
Unrestricted utilization of sirolimus-eluting stent compared with conventional bare stent implantation in the «realworld».
Circulation, 109 (2004), pp. 190-195
[25.]
P.A. Lemos, A. Hoye, D. Goedhart, C.A. Arampatzis, F. Saia, W.J. Van der Giessen, et al.
Clinical, angiographic and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients.
Circulation, 109 (2004), pp. 1366-1370
[26.]
A.T. Ong, P.W. Serruys, J. Aoki, A. Hoye, C.A. Van Mieghem, G.A. Rodríguez-Granillo, et al.
The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population.
J Am Coll Cardiol, 45 (2005), pp. 1135-1141
[27.]
M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser, P. Rickenbacher, P. Hunzicker, C. Mueller, et al.
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents.
J Am Coll Cardiol, 48 (2006), pp. 2584-2591
[28.]
A.A. Bavry, D.J. Kumbhani, T.J. Helton, P.P. Borek, G.R. Mood, D.L. Bhatt.
Late Trombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.
Am J Med, 119 (2006), pp. 1056-1061
[29.]
A. Colombo, S.J. Corbett.
Drug-eluting stent thrombosis. Increasingly recognized but too frequently overemphasized.
J Am Coll Cardiol, 48 (2006), pp. 203-205
[30.]
J.M. Hodgson, G.W. Stone, A.M. Lincoff, L. Klein, H. Walpole, R. Bottner, et al.
Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents. A report from the Society for Cardiovascular Angiography and Interventions Drug-Eluting stent Task Force.
Catheter Cardiovasc Interv, 69 (2007), pp. 327-333
[31.]
M.B. Leon.
Late thrombosis a concern with drug-eluting stents.
J Interven Cardiol, 20 (2007), pp. 26-29
[32.]
J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, C. Morger, et al.
Early and late coronary stent thrombosis of sirolimusand paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.
[33.]
Camenzind E. Safety of drug-eluting stents: Insights from meta-analysis. [accedido 7 Feb 2007]. Disponible en: http://www.escardio.org/knowledge/congresses/CongressReports/hotlinesandctus/707009_Camenzind
[34.]
A.J. Nordmann, M. Briel, H.C. Bucher.
Mortality in randomized controlled trials comparing drug-eluting vs bare metal stents in coronary artery disease: a meta-analysis.
Eur Heart J, 27 (2006), pp. 2784-2814
[35.]
D.R. Holmes, J.W. Moses, J. Schofer, M.C. Morice, E. Schampaert, M.B. Leon.
Cause of death with bare metal and sirolimus-eluting stents.
Eur Heart J, 27 (2006), pp. 2815-2822
[36.]
Y. Honda, P.J. Fitzgerald.
Stent thrombosis. An issue revisited in a changing world.
[37.]
D.E. Cutlip, D.S. Baim, K.K. Ho, J.J. Popma, A.J. Lansky, D.J. Cohen, et al.
Stent thrombosis in the modern era. A pooled analysis of multicenter coronary stent clinical trials.
Circulation, 103 (2001), pp. 1967-1971
[38.]
I. Lakovou, T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, G. Stankovic, et al.
Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents.
JAMA, 293 (2005), pp. 2126-2130
[39.]
P.K. Kuchulakanti, W.W. Chu, R. Torguson, P. Ohlmann, S.W. Rha, L.C. Clavijo, et al.
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
Circulation, 113 (2006), pp. 1108-1113
[40.]
M. Shuchman.
Trading restenosis for thrombosis? New questions about drug-eluting stents.
N Engl J Med, 355 (2006), pp. 1949-1952
[41.]
C. Spaulding, J. Daemen, E. Boersma, D.E. Cutlip, P.W. Serruys.
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
N Engl J Med, 356 (2007), pp. 989-997
[42.]
G.W. Stone, J.W. Moses, S.G. Ellis, J. Schofer, K.D. Dawkins, M.C. Morice, et al.
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
N Engl J Med, 356 (2007), pp. 998-1008
[43.]
A. Kastrati, J. Mehilli, J. Pache, C. Kaiser, M. Valgimigly, H. Kelbaek, et al.
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
N Engl J Med, 356 (2007), pp. 1030-1039
[44.]
M.S. Chen, J.M. John, D.P. Chew, D.S. Lee, S.G. Ellis, D.L. Bhatt.
Bare metal stent restenosis is not a benign clinical entity.
Am Heart J, 151 (2006), pp. 1260-1264
[45.]
D.L. Walters, S.A. Harding, C.R. Walsh, P. Wong, E. Pomerantsev, I.K. Jang.
Acute coronary syndrome is a common clinical presentation of in-stent restenosis.
Am J Cardiol, 89 (2002), pp. 491-494
[46.]
A.R. Assali, A. Moustapha, S. Sdringola, A.E. Denktas, J.T. Willerson, D.R. Holmes, et al.
Acute coronary syndrome may occur with instent restenosis and is associated with adverse outcomes (the PRESTO trial).
Am J Cardiol, 98 (2006), pp. 729-733
[47.]
L. Mauri, W. Hsieh, J.M. Massaro, K.K. Ho, R. D’Agostino, D.E. Cutlip.
Stent thrombosis in randomized clinical trials of drug-eluting stents.
N Engl J Med, 356 (2007), pp. 1020-1029
[48.]
R. Moreno, C. Fernández, R. Hernández, F. Alfonso, D.J. Angiolillo, M. Sabaté, et al.
Drug-eluting stent trombosis. Results from a pooled analysis including 10 randomized studies.
J Am Coll Cardiol, 45 (2005), pp. 954-959
[49.]
T.F. Lüscher, J. Steffel, F.R. Eberli, M. Joner, G. Nakazawa, R. Virmani.
Drug-eluting stent and coronary thrombosis. Biological mechanisms and clinical implications.
Circulation, 115 (2007), pp. 1051-1058
[50.]
J.R. Nebeker, R. Virmani, C.L. Bennett, J.M. Hoffman, M.H. Samore, J. Álvarez, et al.
Hipersensivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Events and Reports (RADAR) project.
J Am Coll Cardiol, 47 (2006), pp. 175-181
[51.]
M.S. Lee, D. Jurewitz, J. Aragon, J. Forrester, R.R. Makkar, S. Kar.
Stent fracture associated with drug-eluting stents: clinical characteristics and implications.
Catheter Cardiovasc Inter, 69 (2007), pp. 387-394
[52.]
J. Ako, Y. Morino, Y. Honda, A. Hassan, S. Sonoda, P.G. Yock, et al.
Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis.
J Am Coll Cardiol, 46 (2005), pp. 1002-1005
[53.]
M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, E. Ladich, et al.
Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk.
J Am Coll Cardiol, 48 (2006), pp. 193-202
[54.]
J. Kotani, M. Awata, S. Nanto, M. Uematsu, F. Oshima, H. Minamiguchi, et al.
Incomplete neointimal coverage of sirolimus-eluting stents. Angioscopic findings.
J Am Coll Cardiol, 47 (2006), pp. 2108-2111
[55.]
J. Oyabu, Y. Ueda, N. Ogasawara, K. Okada, A. Hirayama, K. Kodama.
Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent.
Am Heart J, 152 (2006), pp. 1168-1174
[56.]
Matsumoto D, Shite J, Shinhe T, Otake H, Tanino Y, Ogasawara D, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up evaluated by optical coherence tomography. Eur Heart J [accedido 29 Nov 2006]. Disponible en: 10.1093/eurheartj/ehl413
[57.]
A. Jeremias, B. Sylvia, J. Bridges, A.J. Kirtane, B. Bigelow, D.S. Pinto, et al.
Stent thrombosis after successful sirolimus-eluting stent implantation.
Circulation, 109 (2004), pp. 1930-1932
[58.]
Smith SC Jr, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB III, et al. ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention. Disponible en: www.acc.org/clinical/guidelines/percutaneous/update/index_rev.pdf
[59.]
E.L. Eisenstein, K.J. Anstrom, D.F. Kong, L.K. Shaw, R.H. Tuttle, D.B. Mark, et al.
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
[60.]
C.L. Grines, R.O. Bonow, D.E. Casey Jr, T.J. Gardner, P.B. Lockhart, D.J. Moliterno, et al.
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents.
J Am Coll Cardiol, 49 (2007), pp. 734-739
[61.]
W.H. Maisel.
Unanswered questions- Drug-eluting stents and the risk of late thrombosis.
N Engl J Med, 356 (2007), pp. 981-984
[62.]
B. Lagerqvist, S.K. James, U. Stenestrand, J. Lindbäck, T. Nilsson, L. Wallentin.
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
N Engl J Med, 356 (2007), pp. 1009-1019
[63.]
G. Oliva.
Coste-efectividad de los stents liberadores de fármacos: implicaciones para la práctica clínica y el coste sanitario.
Rev Esp Cardiol, 59 (2006), pp. 865-868
[64.]
A.T. Ong, J. Daemen, B.A. Van Hoult, P.A. Lemos, J.L. Bosch, R.T. Van Domburg, et al.
Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up. Results from the RESEARCH registry.
Eur Heart J, 27 (2006), pp. 2996-3003
[65.]
A.T. Ong, P.W. Serryus.
Technology Insight: an overview of research in drug-eluting stents.
Nat Clin Pract Cardiovasc Med, 12 (2005), pp. 647-658
[66.]
R. Waksman.
Update on bioabsorbable stents: from bench to clinical.
J Interv Cardiol, 19 (2006), pp. 414-421
[67.]
J. Aoki, P.W. Serruys, H. Van Beusekom, A.T. Ong, E.P. McFadden, G. Sianos, et al.
Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry.
J Am Coll Cardiol, 45 (2005), pp. 1574-1579
Copyright © 2007. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología

Suscríbase a la newsletter

Ver histórico de newsletters
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?